Johnson & Johnson Price & Performance (JNJ)

The U.S. Food and Drug Administration has introduced a proposal for standardized asbestos testing in talc products. This move follows extensive litigation linking talc to cancer risks. Companies would need to adopt advanced imaging methods for each batch, with a public comment period open for three months.1

Johnson & Johnson is addressing shareholder concerns regarding executive pay and human rights evaluations ahead of its April 24 meeting. These discussions come as the company reports a quarterly dividend and positive financial updates, including advances in ulcerative colitis treatments and FDA approval for a depression therapy.2

Johnson & Johnson shares have seen varied ratings from analysts recently. While some maintain optimistic price targets, others have downgraded expectations. Despite outperforming the S&P 500 this year, concerns about valuation and growth prospects persist, particularly in light of mixed financial performance in recent quarters.3